Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33

Hepatology

Volumn 43, Issue 3, 2006, Pages 592-601

  Tarr, Alexander W ^a   Owsianka, Ania M ^b   Timms, Judith M ^a   McClure, C Patrick ^a   Brown, Richard J P ^a   Hickling, Timothy P ^a   Pietschmann, Thomas ^c   Bartenschlager, Ralf ^c   Patel, Arvind H ^b   Ball, Jonathan K ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTIGEN; EPITOPE; GLYCOPROTEIN E2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AP33; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; CELL CULTURE; GENE MAPPING; GENETIC CONSERVATION; GENOTYPE; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CELL LINE; EPITOPES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HUMANS; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; PROTEIN CONFORMATION; VIRAL ENVELOPE PROTEINS;

EID: 33645310928     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21088     Document Type: Article

References (52)

1. Anonymous. Global surveillance and control of hepatitis C. J Viral Hepatol 1999;6:35-47.
2. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003;197:633-642.
3. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003;100:7271-7276.
4. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005;102:9294-9299.
5. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao ZJ, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med 2005;11:791-796.
6. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-626.
7. Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci U S A 2003;100:4498-4503.
8. Pohlmann S, Zhang J, Baribaud F, Chen Z, Leslie GJ, Lin G, et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 2003;77:4070-4080.
9. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002;21:5017-5025.
10. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-941.
11. Barth H, Cerino R, Arcuri M, Hoffmann M, Schurmann P, Adah MI, et al. Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol 2005;79:5774-5785.
12. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005;79:8217-8229.
13. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. HEPATOLOGY 2005;41:265-274.
14. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptot class B type I. J Biol Chem 2005;280:7793-7799.
15. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
16. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
17. Simmonds P. The origin and evolution of hepatitis viruses in humans. J Gen Virol 2001;82:693-712.
18. Abrignani S, Rosa D. Perspectives for a hepatitis C virus vaccine. Clin Diagn Virol 1998;10:181-185.
19. Allander T, Drakenberg K, Beyene A, Rosa D, Abrignani S, Houghton M, et al. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol 2000;81:2451-2459.
20. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, et al. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 2000;74:10407-10416.
21. Shang D, Zhai W, Allain JP. Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits. Virology 1999;258:396-405.
22. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 1999;73:6235-6244.
23. Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 2001;82:1877-1883.
24. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 1996;93:1759-1763.
25. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994;68:1494-1500.
26. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody- mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994;91:7792-7796.
27. Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 2003;100:14199-14204.
28. Allander T, Drakenberg K, Beyene A, Rosa D, Abrignani S, Houghton M, et al. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol 2000;81:2451-2459.
29. Habersetzer F, Fourmilier A, Dubuisson J, Rosa D, Abrignani S, Wychowski C, et al. Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology 1998;249:32-41.
30. Ishii K, Rosa D, Watanabe Y, Katayama T, Harada H, Wyatt C, et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. HEPATOLOGY 1998;28:1117-1120.
31. Bugli F, Mancini N, Kang C-Y, Di Campli C, Grieco A, Manzin A, et al. Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol 2001;75:9986-9990.
32. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, et al. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 2000;74:10407-10416.
33. Puig M, Major ME, Mihalik K, Feinstone SM. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 2004;22:991-1000.
34. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset F-L, et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 2005;79:11095-11104.
35. Triyatni M, Vergalla J, Davis AR, Hadlock KG, Foung SKH, Liang TJ. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology 2002;298:124-132.
36. Flint M, Dubuisson J, Maidens C, Harrop R, Guile GR, Borrow P, et al. Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. J Virol 2000;74:702-709.
37. Patel AH, Wood J, Penin F, Dubuisson J, McKeating JA. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol 2000;81:2873-2883.
38. Clayton RF, Owsianka A, Aitken J, Graham S, Bhella D, Patel AH. Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol 2002;76:7672-7682.
39. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and sindbis viruses. J Virol 1994;68:6147-6160.
40. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982;42:3858-3863.
41. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997;25:4876-4882.
42. Moore JP, Thali M, Jameson BA, Vignaux F, Lewis GK, Poon SW, et al. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J Virol 1993;67:4785-4796.
43. Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A 1997;94:8738-8743.
44. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-626.
45. Friebe P, Boudet J, Simorre JP, Bartenschlager R. Kissing-loop interaction in the 3′ end of the hepatitis C virus genome essential for RNA replication. J Virol 2005;79:380-392.
46. McCafferty J, Johnson KS. Construction and screening of antibody display libraries. In: Kay BK, Winter J, McCafferty J, eds. Phage Display of Peptides and Proteins: A Laboratory Manual. San Diego, CA: Academic Press, 1996:79-111.
47. Wang ZD, Raifu M, Howard M, Smith L, Hansen D, Goldsby R, et al. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3′ to 5′ exonuclease activity. J Immunol Methods 2000;233:167-177.
48. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001;75:10892-10905.
49. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset F-L, Montpellier C, et al. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 2005;79:8400-8409.
50. Melzer H, Fortugno P, Mansouri E, Felici F, Mariners A, Wiedermann G, et al. Antigenicity and immunogenicity of phage library-selected peptide mimics of the major surface proteophosphoglycan antigens of Entamoeba histolytica. Parasite Immunology 2002;24:321-328.
51. Morea V, Tramontano A, Rustici M, Chothia C, Lesk AM. Conformations of the third hypervariable region in the VH domain of immunoglobulins. J Mol Biol 1998;275:269-294.
52. Shirai H, Kidera A, Nakamura H. Structural classification of CDR-H3 in antibodies. FEBS Lett 1996;399:1-8.